Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 17466735.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess the reliability, validity, responsiveness, and minimally important difference (MID) of the Incontinence Quality of Life (I-QOL) questionnaire in patients with urinary incontinence due to neurogenic detrusor overactivity. Randomized, double-blind, multicenter, placebo-controlled study. Eight centers across Belgium, France, and Switzerland. Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed on oral anticholinergics. Fifty-nine patients (spinal cord injury, n=53; multiple sclerosis, n=6) were enrolled. Single dose of botulinum toxin type A (Botox) (200 or 300 U) or placebo. I-QOL questionnaire completed at screening and over a 24-week post-treatment period. The Cronbach alpha ranged from .79 to .93, indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinence patients. No item had more than 5.1% missing or out of range values. With the exception of 2 items, questions showed acceptable item-scale correlation and scaling success results varied by domain. Post-treatment correlations indicated acceptable construct validity. The I-QOL was responsive to improvements in symptoms. MID values ranged from 4 to 11 points. Results suggest that I-QOL is a reliable, valid, and responsive measure of incontinence-related QOL in neurogenic patients.
Medical subject headings
- Quality of Life
- Surveys and Questionnaires
- Urinary Bladder, Neurogenic